Influenza, Human: all 2,264 studies
Page 23 of 23. Open to participants first (173), then studies with results posted, then the rest; newest registration first within each.
- Immunogenicity and Safety of Different Doses of Fluzone® InfluenzaCompletedNCT00253734Phase 2
- Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of AgeCompletedNCT00242424Phase 2/3
- H5 Booster After a Two Dose ScheduleCompletedNCT00240968Phase 2
- Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) VaccineCompletedNCT00240903Phase 1
- Catechin Gargling for Influenza InfectionCompletedNCT00239213Not applicable
- Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and OverCompletedNCT00232947Phase 3
- Inactivated Influenza Vaccine in Infants 10-22 Weeks of AgeCompletedNCT00231920Phase 1
- A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and FlumistCompletedNCT00231907Phase 1
- Inactivated Influenza A/H5N1 Vaccine in the ElderlyCompletedNCT00230750Phase 1/2
- Influenza Vaccination and Oral Anticoagulant TherapyCompletedNCT00222638Phase 4
- Effectiveness of Influenza Vaccination Among General PractitionersCompletedNCT00221676Phase 4
- Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And OlderCompletedNCT00217230Phase 3
- Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.Status unknownNCT00216242Phase 3
- The Effect of Needle Temperature on Pain Ratings Following Intramuscular InjectionCompletedNCT00213967Not applicable
- Influenza Vaccine in Lung Transplant PatientsCompletedNCT00205270
- Liposomal Based Intranasal Influenza Vaccine:Safety and EfficacyCompletedNCT00197301Phase 1/2
- Study Comparing the Immune Response of Fluarix and Fluzone Influenza VaccinesCompletedNCT00197288Phase 3
- Post-marketing Study to Evaluate the Efficacy of Influenza VaccineCompletedNCT00197223Phase 3
- Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy ChildrenCompletedNCT00192491Phase 3
- Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed InfluenzaCompletedNCT00192413Phase 3
- Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)CompletedNCT00192387Phase 2
- Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)CompletedNCT00192361Phase 3
- Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy ChildrenCompletedNCT00192322Phase 2
- Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.CompletedNCT00192309Phase 2
- Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care CentersCompletedNCT00192283Phase 3
- Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With AsthmaCompletedNCT00192257Phase 3
- Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)CompletedNCT00192231Phase 3
- Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention ProgramCompletedNCT00192218Phase 4
- Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in ChildrenCompletedNCT00192205Phase 3
- Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy AdultsCompletedNCT00192192Phase 3
- A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.CompletedNCT00192179Phase 2
- Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 MonthsCompletedNCT00192166Phase 2
- Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and OlderCompletedNCT00192153Phase 2
- Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy AdultsCompletedNCT00192127Phase 3
- Comparison of Delivery Routes of Flu Vaccine in AdultsCompletedNCT00170547Phase 2
- Young Adult Influenza Vaccine Immunogenicity SubstudyCompletedNCT00170508Not applicable
- Elderly Influenza Vaccine Immunogenicity SubstudyCompletedNCT00170482
- Trivalent rHA Dose Escalation Study in Elderly SubjectsCompletedNCT00170443Phase 2
- Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004CompletedNCT00161837Phase 2/3
- Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005CompletedNCT00161811Phase 2/3
- A Comparison of One Versus Two Doses of Influenza Vaccine in Children 5-8 Years of AgeCompletedNCT00158665Not applicable
- Rapid Vaccination of Hard-To-Reach PopulationsStatus unknownNCT00155974Not applicable
- Study to Eliminate Hib Carriage in Rural Alaska Native VillagesCompletedNCT00153556Phase 4
- Electronic Health Records for Health PromotionCompletedNCT00142077Not applicable
- T-cell Response-Flu Risk in Older AdultsCompletedNCT00138398Not applicable
- Comparison of Inactivated and Live, Attenuated Influenza Vaccine in Children 5-9 Years of Age-Year 3 AmendmentCompletedNCT00138385Phase 4
- Influenza Immunity Against Pandemic Respiratory VirusCompletedNCT00138281Phase 4
- Safety of the Intramuscular Route of the Anti-Flu Vaccine in Patients Receiving Oral Anticoagulation TherapyCompletedNCT00137579Phase 4
- Study of a Pandemic Influenza VaccineCompletedNCT00136331Phase 1
- Proteomic Profiling for InfluenzaCompletedNCT00133588Phase 4
- A/H5N1 Vaccine in Healthy Children Aged 2-9 YearsCompletedNCT00133536Phase 1/2
- FLU-VACS Comparative Study in AdultsCompletedNCT00133523Phase 4
- Influenza Vaccine in Pediatric Transplant SubjectsCompletedNCT00133510Phase 4
- Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory AdultsCompletedNCT00133471Phase 1/2
- Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of AgeCompletedNCT00128167Phase 3
- Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy AdultsCompletedNCT00125944Phase 3
- A/H5N1in Adult - AventisCompletedNCT00115986Phase 1/2
- Eldery High Dose TIV 2005CompletedNCT00115531Phase 2
- Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)CompletedNCT00111579Phase 2
- Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)CompletedNCT00110279Phase 1
- Fluarix Immunogenicity and Safety TrialCompletedNCT00100399Phase 3
- Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and AdolescentsCompletedNCT00091702Phase 1/2
- Half-Dose Flu Vaccine Study in Healthy AdultsCompletedNCT00006146Phase 2
- Study of a Flu Vaccine in ChildrenCompletedNCT00001127Phase 3